Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of medioresinol in preparation of drug for preventing or treating cerebral injury and pharmaceutical composition thereof

A resin alcohol, brain injury technology, applied in the field of medicine to achieve the effect of reducing injury

Active Publication Date: 2020-03-31
江苏征瑞医药科技有限公司
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

No relevant studies have reported its biological activity so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of medioresinol in preparation of drug for preventing or treating cerebral injury and pharmaceutical composition thereof
  • Application of medioresinol in preparation of drug for preventing or treating cerebral injury and pharmaceutical composition thereof
  • Application of medioresinol in preparation of drug for preventing or treating cerebral injury and pharmaceutical composition thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Determination of the release of lactate dehydrogenase LDH and the expression of inflammatory factor IL-1β in cells:

[0033] Brain vascular endothelial cells (bEND3) were pretreated with corticosteroids (20 μM) for 12 hours, then the medium was removed, the medium was replaced with sugar-free medium, and placed in an anoxic incubator for 6 hours. The hydrogenase detection kit was used to detect lactate dehydrogenase (LDH) released by vascular endothelial cells (Shanghai Beyond Biotechnology Co., Ltd.), and the adherent cells were collected at the same time, and the mRNA expression of inflammatory factor IL-1β in vascular endothelial cells was detected by RT-PCR .

[0034] (1) Establishment of endothelial cell injury model in vitro by oxygen-glucose deprivation (OGD):

[0035] The mouse brain microvascular endothelial cell line bEND3 was injected at 1×10 5 The density of cells / ml was inoculated on a 24-well plate pre-coated with type I collagen, and after 24 hours of s...

Embodiment 2

[0051] Determination of the permeability of the blood-brain barrier established by the co-culture of primary cerebral microvascular endothelial cells and astrocytes: Firstly, the co-culture model of cerebral microvascular endothelial cells and astrocytes was established. A 24-well cell culture plate and the inside and back of the Millicell chamber were coated with rat tail collagen and allowed to dry. Astrocytes were inoculated on the back side of the Millicell culture chamber, and cultured in the incubator for 6 hours. After the astrocytes were completely attached to the wall, the Millicell culture chamber was placed in a 24-well cell culture plate, and the brain microvascular endothelial cells Inoculated on the inner side of the Millicell culture chamber, cultured with the growth medium of brain microvascular endothelial cells. After the model was successful, the cells were treated with corticoresinol (20μM) for 12h and then treated with OGD for 6h. The effect of corticoresi...

Embodiment 3

[0062] Establishment of mouse middle cerebral artery occlusion (tMCAO) model and measurement of cerebral infarction volume:

[0063] (1) Establishment of mouse tMCAO model

[0064] The mouse tMCAO model refers to the internal carotid artery suture method of Longa et al. The main operation steps are as follows: weigh male C57 / BL6 mice weighing about 25-30g, place them in an anesthesia induction box, give 3%-4% isoflurane to induce anesthesia, and place the mice in a supine position after anesthesia Fixed on the operating table. The mice were put on a breathing mask and given 1.0%-2.0% isoflurane to maintain anesthesia. Wipe the mouse neck skin with 75% alcohol cotton ball, incise the skin in the middle of the neck, and bluntly separate the layers of muscle and soft tissue with curved forceps, expose the right common carotid artery, and put a nylon thread for use. The soft tissue was bluntly dissected from the head side of the mouse along the common carotid artery to expose t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of medioresinol in preparation of a drug for preventing or treating the cerebral injury and a pharmaceutical composition thereof. The invention provides applicationof medioresinol in preparation of a drug for preventing or treating the cerebral injury for the first time; the medioresinol has an obvious effect on prevention or treatment of the cerebral injury, especially the cerebral injury caused by the cerebral arterial thrombosis; and the cerebral injury caused by the cerebral arterial thrombosis can be obviously reduced. The experiment discovers that themedioresinol has an effect of inhibiting brain microvascular endothelial cell damage caused by oxygen-glucose deprivation and is capable of obviously reducing the permeability of a blood brain barrier under oxygen-glucose deprivation. The medioresinol can reduce the volume of cerebral infarction under middle cerebral artery occlusion remarkably. The pharmaceutical composition containing the medioresinol can become a novel drug for preventing and / or treating the cerebral injury and is used for treating various cerebrovascular diseases including cerebral arterial thrombosis.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the use of corticosterol in the preparation of medicines for preventing or treating brain damage and its pharmaceutical composition. Background technique [0002] Stroke is a refractory disease that seriously endangers human health and life safety in the world today. It is characterized by high morbidity, high disability, high recurrence and high mortality. my country is the country with the most serious disease burden of stroke in the world. In China, there are about 2 million new stroke patients every year, of which ischemic stroke accounts for about 75% to 85% of the total number of stroke patients. The annual treatment cost for this disease in the country is more than 10 billion yuan, which is a great contribution to the country and families. caused a heavy economic burden. In the past two decades, a large number of studies have shown that neuroprotective agents can effecti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/34A61P7/10A61P7/04A61P9/10A61P25/00
CPCA61K31/34A61P7/10A61P7/04A61P9/10A61P25/00
Inventor 庞涛阮文臣河泰麟王云杰高成龙张陆勇
Owner 江苏征瑞医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com